Myriad Will Seek FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Olaparib
Trial results confirm the potential benefits of using biomarkers to guide care for men with metastatic castration-resistant prostate cancer.
Read MoreSearch Results for: prostate cancer
Study: Prolaris Test Accurately Predicts Risk of Prostate Cancer Metastases
The study’s objective was to evaluate the ability of the Prolaris test and the Prolaris test combined with clinical information to predict a patient’s 10-year risk of progression to metastatic disease.
Read More
Liquid Biopsies Guide Improved Cancer Treatment
Monitoring cancer therapy in real time enables physicians to make smarter treatment decisions.
Read More
Test for Resistance Markers May Improve Treatment for Advanced Prostate Cancer
The researchers envision that their discovery may eventually result in a test that contributes to more personalized treatment of metastatic castration-resistant prostate cancer.
Read MoreAstraZeneca, Merck, and Myriad Expand Partnership for Cancer Diagnostics Research
Myriad’s BRACAnalysis companion diagnostic will be used to identify germline BRCA mutations in men with metastatic castration-resistant prostate cancer.
Read More